Mixed Results With Leukemia Drug in Parkinson ' s Mixed Results With Leukemia Drug in Parkinson ' s

The authors say low doses of nilotinib were ' reasonably safe ' in this phase 2 trial, an assessment questioned by authors of an accompanying editorial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news